Clinical trials: Schizo Affective Disorder
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Alcohol Use Disorder, Bipolar Disorder
Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders
Preclinical and clinical data as well as mechanistic justification have been presented suggesting citicoline and pregnenolone are each promising treatments for alcohol use in BPD.
- Conditions
- Alcohol Use Disorder, Bipolar Disorder, Schizoaffective Disorder Bipolar Type
- Trial name
- NCT02582905
- Testing
- Citicoline, Pregnenolone
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sherwood Brown, MD, PhD
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Bipolar Disorder, Alcoholism
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
The investigators will conduct a 12-week, randomized, double-blind, parallel-group, placebo-controlled study of aripiprazole in 132 persons with Alcohol Use Disorder (AUD) and bipolar I or II disorder, currently depressed or…
- Conditions
- Bipolar Disorder, Alcoholism, Alcohol Abuse
- Trial name
- NCT02918370
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of different dosages (from 3 mg/day to 12 mg/day) of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute…
- Trial name
- NCT00412373
- Testing
- Paliperidone ER
- Where
- 44 sites in United States, India and 4 more
- Volunteers
- 307 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle gating across species," to extend a clear path of "bench-to-bedside" progress towards a critical paradigm shift in therapeutic models for…
- Trial name
- NCT02634684
- Testing
- Dextroamphetamine
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Polypharmacy in Clozapine-resistant Schizophrenia
The aim of this randomized, double-blind study is to verify the hypothesis that clozapine monotherapy is as efficient as a combination of clozapine and olanzapine therapy in treatment-resistant schizophrenia.
- Trial name
- CLOZANS (NCT00918021)
- Testing
- olanzapine
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Niuvanniemi Hospital
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03004 following an escalating single intramuscular injection at 12.5, 25, 37.5, or 50 mg; and to evaluate the safety and tolerability and preliminary…
- Trial name
- LY03004SAD (NCT02055287)
- Testing
- LY03004
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
Nicotinic Receptors and Schizophrenia
The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are…
- Trial name
- NCT01400477
- Testing
- DMXB-A-SR
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of Colorado, Denver
Schizophrenia, Schizoaffective Disorder
Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training.
- Trial name
- NCT00148083
- Testing
- Risperdal Consta (drug), Social Skills Training
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Illinois at Chicago
Schizophrenia, Schizoaffective Disorder
Characterizing Response to Antipsychotics in Schizophrenia
The goal of this research project is to develop MRI-based biomarkers to identify patients with schizophrenia who are most likely to benefit from first-line antipsychotic or clozapine treatment.
- Trial name
- NCT06159322
- Testing
- Olanzapine, Clozapine
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia
Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia
This study evaluated the effectiveness of Cognitive Behavioral Social Skills Training versus goal-focused supportive contact in improving social functioning in people with schizophrenia.
- Trial name
- NCT00338975
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal-focused supportive contact (GFSC), Social Skills Training
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia, Schizoaffective Disorder
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00538642
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients Taking Part in Integrated Care Program
Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreni-form Disorder, Delusional Disorder
- Trial name
- CARE I (NCT00617214)
- Where
- 14 sites in Germany
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
It has been suggested that patients with schizophrenia smoke in order to produce amelioration of dysfunctional dopaminergic pathways allowing them to experience pleasure and satisfaction and overcome anhedonia.
- Trial name
- NCT00373126
- Testing
- transdermal nicotine patch
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Bipolar Disorders, Schizophrenia
Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
The primary aim of this study is to determine the feasibility of long-acting injectable naltrexone administration in a clinical trial in patients with SMI who also have a diagnosis of alcohol dependence.
- Conditions
- Bipolar Disorders, Schizophrenia, Schizoaffective Disorders, Alcohol Dependence
- Trial name
- vivitrol (NCT00453804)
- Testing
- injectable naltrexone, oral naltrexone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- State University of New York - Upstate Medical University
Schizophrenia, Psychosis
Enhancing Rehabilitation for Veterans With Serious Mental Illness
This study addresses the critical need for innovative therapeutic interventions in Veterans with serious mental illnesses (SMI) receiving care in VA Psychosocial Rehabilitation and Recovery Centers (PRRCs).
- Conditions
- Schizophrenia, Psychosis, Serious Mental Illness, PTSD
- Trial name
- NCT06586164
- Testing
- Targeted Cognitive Training
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Bipolar Disorder
Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness
Development of interventions that can effectively target and remediate the cognitive and functional impairment associated with serious mental illness is a treatment priority.
- Conditions
- Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
- Trial name
- NCT03208036
- Testing
- TDCS, Cognitive Remediation, Bridging Group
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizo Affective Disorder
Intervention Targeting Motivational Negative Symptoms
This study aims to investigate the effects of the Switch intervention on motivation and associated processes and explore the dynamics between the processes.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- Switch (NCT04325100)
- Testing
- Switch - Individual sessions, Switch - Group programme
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University of Liege
Schizoaffective Disorder, Schizophrenia
Motivational Interviewing to Improve Work Outcomes in Schizophrenia
Many persons with schizophrenia have difficulty getting and keeping a job. This study is designed to compare the benefits of four sessions of motivational interviewing or illness education in increasing employment rates accruing…
- Trial name
- NCT00261716
- Testing
- IPS, IE, VOMI
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- VA Office of Research and Development